Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in mono...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo
Formato:	article
Lenguaje:	EN
Publicado:	Society for Publication of Acta Dermato-Venereologica 2021
Materias:	risankizumab psoriasis real-life Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/20c28872390140f28af22f527d4296d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:20c28872390140f28af22f527d4296d6
record_format	dspace
spelling	oai:doaj.org-article:20c28872390140f28af22f527d4296d62021-11-30T14:25:13ZReal-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study10.2340/actadv.v101.2830001-55551651-2057https://doaj.org/article/20c28872390140f28af22f527d4296d62021-11-01T00:00:00Zhttps://medicaljournalssweden.se/actadv/article/view/283https://doaj.org/toc/0001-5555https://doaj.org/toc/1651-2057Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a “real-life” setting. At week 40, 98.7%, 85.7% and 62.3% of patients achieved a Psoriasis Area and Severity Index (PASI) reduction ≥ 75% (PASI 75), PASI 90 and PASI 100, respectively. Patients who had not responded to 2 or more previous biologic treatments were significantly less likely to achieve PASI 75/90 at week 16 and PASI 90/100 at week 40 compared with those who had been previously treated with only 1 biologic, and compared with those treated with risankizumab as a first-line biologic. Increasing body mass index decreased the chances of reaching PASI 90 at week 40. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment. These data suggest that the efficacy of risankizumab for plaque psoriasis in “real-life” clinical practice could differ from pivotal clinical trials data. Riccardo G. BorroniPiergiorgio MalagoliLuigi Gargiulo Mario ValentiGiulia PaviaPaola FacherisEmanuela MorenghiIsotta Giunipero di CorteranzoAlessandra NarcisiMichela OrtoncelliPaolo DapavoAntonio CostanzoSociety for Publication of Acta Dermato-Venereologicaarticlerisankizumabpsoriasisreal-lifeDermatologyRL1-803ENActa Dermato-Venereologica, Vol 101, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	risankizumab psoriasis real-life Dermatology RL1-803
spellingShingle	risankizumab psoriasis real-life Dermatology RL1-803 Riccardo G. Borroni Piergiorgio Malagoli Luigi Gargiulo Mario Valenti Giulia Pavia Paola Facheris Emanuela Morenghi Isotta Giunipero di Corteranzo Alessandra Narcisi Michela Ortoncelli Paolo Dapavo Antonio Costanzo Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
description	Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a “real-life” setting. At week 40, 98.7%, 85.7% and 62.3% of patients achieved a Psoriasis Area and Severity Index (PASI) reduction ≥ 75% (PASI 75), PASI 90 and PASI 100, respectively. Patients who had not responded to 2 or more previous biologic treatments were significantly less likely to achieve PASI 75/90 at week 16 and PASI 90/100 at week 40 compared with those who had been previously treated with only 1 biologic, and compared with those treated with risankizumab as a first-line biologic. Increasing body mass index decreased the chances of reaching PASI 90 at week 40. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment. These data suggest that the efficacy of risankizumab for plaque psoriasis in “real-life” clinical practice could differ from pivotal clinical trials data.
format	article
author	Riccardo G. Borroni Piergiorgio Malagoli Luigi Gargiulo Mario Valenti Giulia Pavia Paola Facheris Emanuela Morenghi Isotta Giunipero di Corteranzo Alessandra Narcisi Michela Ortoncelli Paolo Dapavo Antonio Costanzo
author_facet	Riccardo G. Borroni Piergiorgio Malagoli Luigi Gargiulo Mario Valenti Giulia Pavia Paola Facheris Emanuela Morenghi Isotta Giunipero di Corteranzo Alessandra Narcisi Michela Ortoncelli Paolo Dapavo Antonio Costanzo
author_sort	Riccardo G. Borroni
title	Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
title_short	Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
title_full	Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
title_fullStr	Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
title_full_unstemmed	Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
title_sort	real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study
publisher	Society for Publication of Acta Dermato-Venereologica
publishDate	2021
url	https://doaj.org/article/20c28872390140f28af22f527d4296d6
work_keys_str_mv	AT riccardogborroni reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT piergiorgiomalagoli reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT luigigargiulo reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT mariovalenti reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT giuliapavia reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT paolafacheris reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT emanuelamorenghi reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT isottagiuniperodicorteranzo reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT alessandranarcisi reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT michelaortoncelli reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT paolodapavo reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy AT antoniocostanzo reallifeeffectivenessandsafetyofrisankizumabinmoderatetosevereplaquepsoriasisa40weekmulticentricretrospectivestudy
_version_	1718406492281896960

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Ejemplares similares